Technical Analysis for AFMD - Affimed Therapeutics B.V.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| See historical AFMD trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jan 18 | Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% |
| Jan 18 | Inside Day | Range Contraction | 0.00% |
| Jan 18 | Wide Bands | Range Expansion | 0.00% |
| Jan 17 | Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -0.28% |
| Jan 17 | Inside Day | Range Contraction | -0.28% |
| Jan 17 | Wide Bands | Range Expansion | -0.28% |
| Jan 16 | Wide Bands | Range Expansion | -1.39% |
| Jan 14 | Narrow Range Bar | Range Contraction | 4.12% |
| Jan 14 | NR7 | Range Contraction | 4.12% |
| Jan 14 | Down 3 Days in a Row | Weakness | 4.12% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-07
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
Affimed Therapeutics B.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate includes AFM13, a natural killer cell bispecific antibody (TandAb) that has completed a Phase I clinical trial for the treatment of certain CD30-positive (CD30+) B- and T-cell malignancies, including hodgkin lymphoma. The company's product candidates also comprise AFM11, a T-cell TandAb for the treatment of certain CD19+ B-cell malignancies, including non-hodgkin lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor variant III for solid tumors, as well as for patients with glioblastoma, hormone refractory prostate cancer, and head and neck cancer. Affimed Therapeutics B.V. has license agreements with Amphivena Therapeutics, Inc. to develop a product candidate for hematologic malignancies; and Xoma Ireland Limited to conduct research on immunoglobulins. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more AFMD news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 7.35 |
| 52 Week Low | 1.3 |
| Average Volume | 738,879 |
| 200-Day Moving Average | 2.9295 |
| 50-Day Moving Average | 3.7316 |
| 20-Day Moving Average | 3.2795 |
| 10-Day Moving Average | 3.512 |
| Average True Range | 0.2457 |
| ADX | 20.41 |
| +DI | 25.5298 |
| -DI | 14.3725 |
| Chandelier Exit (Long, 3 ATRs ) | 3.1029 |
| Chandelier Exit (Short, 3 ATRs ) | 3.5271 |
| Upper Bollinger Band | 3.7938 |
| Lower Bollinger Band | 2.7652 |
| Percent B (%b) | 0.75 |
| BandWidth | 31.364537 |
| MACD Line | -0.011 |
| MACD Signal Line | -0.0704 |
| MACD Histogram | 0.0594 |
| Fundamentals | Value |
|---|---|
| Market Cap | 155.54 Million |
| Num Shares | 43.9 Million |
| EPS | -0.99 |
| Price-to-Earnings (P/E) Ratio | -3.56 |
| Price-to-Sales | 22.02 |
| Price-to-Book | 1.82 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.75 | ||||
| Resistance 3 (R3) | 3.75 | 3.67 | 3.72 | ||
| Resistance 2 (R2) | 3.67 | 3.62 | 3.68 | 3.70 | |
| Resistance 1 (R1) | 3.61 | 3.59 | 3.57 | 3.61 | 3.69 |
| Pivot Point | 3.53 | 3.53 | 3.52 | 3.54 | 3.53 |
| Support 1 (S1) | 3.47 | 3.48 | 3.43 | 3.47 | 3.39 |
| Support 2 (S2) | 3.39 | 3.45 | 3.40 | 3.38 | |
| Support 3 (S3) | 3.33 | 3.39 | 3.37 | ||
| Support 4 (S4) | 3.33 |
